Juvenile idiopathic inflammatory myopathies after COVID-19 infection
In a recent study, racial minorities of an older age with non-classic cutaneous manifestations were more often to present with juvenile idiopathic inflammatory myopathies after COVID-19 infection.
Updates on FDA drug approvals
At ACR Convergence 2022, Amit Golding, MD, PhD, outlined drugs recently approved by the FDA, and discussed the requirements for biosimilars to meet approval.
How the FDA prevents drug shortages
At ACR Convergence 2022, Hyun Son, PharmD, discussed the role of the FDA’s Drug Shortage Staff in preventing and mitigating drug shortages.
